CAR T-cell therapy uses the target specificity of antibody therapy to direct the cytotoxic immune response4

The autologous anti-CD19 CAR T-cell therapy, TECARTUS, is individually prepared from each patient’s T cells in a 6-step process1:

Leukapheresis

Leukapheresis

Obtain peripheral blood mononuclear cells

T cells

Selection

Isolate T cells to reduce the likelihood that circulating tumor cells drive the exhaustion of CAR T cells

anti-CD3 and anti-CD28 antibodies + IL-2

Activation

Activate T cells using anti-CD3 and anti-CD28 antibodies + IL-2

anti-CD19 CAR transgene

Transduction

Insert anti-CD19 CAR transgene

CAR T cell expansion

T Cell Expansion

In cell culture, expand the number of CAR T cells to achieve dose

CAR T cells in suspension for infusion

Suspension

Formulate CAR T cells into suspension for infusion

CAR=chimeric antigen receptor; FDA=Food and Drug Administration; IL=interleukin.

References: 1. TECARTUS® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2021. 2. KYMRIAH® (tisagenlecleucel). Prescribing information. Novartis Pharmaceuticals Corporation; 2021. 3. Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491-502. 4. Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94(S1):S3-S9.